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Geolycosa sp. spider venomRecently, the novel peptide named purotoxin-1 (PT1) has been identiﬁed in the venom of the spider Geolycosa
sp. and shown to exert marked modulatory effects on P2X3 receptors in rat sensory neurons. Here we studied
another polypeptide from the same spider venom, purotoxin-2 (PT2), and demonstrated that it also affected
activity of mammalian P2X3 receptors. The murine and human P2X3 receptors were heterologously expressed
in cells of the CHO line, and nucleotide-gated currents were stimulated by CTP and ATP, respectively. Both PT1
and PT2 negligibly affected P2X3-mediated currents elicited by brief pulses of the particular nucleotide. When
subthreshold CTP or ATP was added to the bath to exert the high-afﬁnity desensitization of P2X3 receptors,
both spider toxins strongly enhanced the desensitizing action of the ambient nucleotides. At the concentration
of 50 nM, PT1 and PT2 elicited 3–4-fold decrease in the IC50 dose of ambient CTP or ATP. In contrast, 100 nM
PT1 and PT2 negligibly affected nucleotide-gated currents mediated by mP2X2 receptors or mP2X2/mP2X3
heteromers. Altogether, our data point out that the PT1 and PT2 toxins speciﬁcally target the fast-desensitizing
P2X3 receptor, thus representing a unique tool to manipulate its activity.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Extracellular ATP is a signaling molecule that mediates diverse
cellular functions via multiple metabotropic P2Y and ionotropic P2X
purinoreceptors [1–3]. P2X receptors are homo- or heterotrimers formed
by P2X1–P2X7 subunits (in humans) that function as ATP-gated cation
channels [4,5]. Although most P2X subunits are widely distributed
among cell types of nearly every origin, expression of the P2X3 subunit
is rather speciﬁc. Reportedly, P2X3 mRNA and/or protein locate largely
in small-diameter sensory neurons, some epithelial cells, carotid body af-
ferent neurons, enteric neurons, and taste buds [6–12]. The highly selec-
tive distribution of P2X3 and P2X2/3 receptors within the nociceptive
system, including C-ﬁber sensory neurons detecting noxious stimuli in
damaged or sensitized tissues, suggests P2X3 to be involved in pain sen-
sation. This inference is strongly supported by studies of animals devoid
of P2X3. Particularly, the genetic ablation of the p2x3 gene in mice
resulted in amarkedly attenuated nocifensive phenotype, including a de-
creased sensitivity to thermal stimuli and injection of carrageenan or for-
malin [13]. Mice devoid of P2X3 or P2X2/3 receptors exhibited sensory
deﬁcit, including urinary and intestinal hyporeﬂexia and diminishedr will appear in the UniProt
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iology of visceral organs and the peripheral taste system [13–17]. It thus
appears that the P2X3 subunit is involved in sensitization of somatic
and visceral afferent circuits of many types. Accordingly, P2X3-based
ATP-gated channels are of signiﬁcant therapeutic interest as a likely tar-
get for the treatment of certain types of pain and disorders of the
visceral sensory function [18].
As showed in the recent report [19], a peptide isolated from the
venomof the spiderGeolycosa sp. exertedmarked and speciﬁc inhibition
of P2X3 receptors operating in sensory neurons from the rat dorsal root
ganglion.When tested in animalmodels of inﬂammatory pain, this novel
peptide named purotoxin-1 (PT1) manifested marked antinociceptive
action [19]. Here we studied effects of PT1 and another polypeptide
named purotoxin-2 (PT2) from the same spider venom on ATP-gated
currents mediated by murine and human P2X3 receptors. Those were
heterologously expressed in CHO cells. We found that both molecules,
quite dissimilar in terms of primary structure, markedly enhanced the
high-afﬁnity desensitization of P2X3 receptors, thereby presenting a
unique tool for manipulating activity of this purinoreceptor.
2. Methods
2.1. Chromatography
Our generally applied scheme of spider venom separation was
reported earlier [20]. Crude venom of the spider Geolycosa sp. (spp.
2869N.V. Kabanova et al. / Biochimica et Biophysica Acta 1818 (2012) 2868–2875code — A267TDLS2-KZARNA) was obtained from Fauna Laboratories
(Republic of Kazakhstan). The separation of the venom was carried
out as described [19]. The pure polypeptide toxin named purotoxin-2
(PT2) was isolated using a combination of size-exclusion and reverse-
phase high performance liquid chromatography (RP-HPLC) with a TSK
2000SW column (Toyo Soda Manufacturing). The fraction I was further
separated by RP-HPLC on a Vydac 218TP54 C18 column (Separations
Group).
2.2. Mass spectrometry (MS) and UV absorbance spectroscopy
Peptides were analyzed by MALDI MS and MS/MS as described
[19,20]. An ultraﬂex TOF–TOF (Bruker Daltonik) spectrometer was used.
Absorption spectra were recorded on a U-3210 spectrophotometer
(Hitachi, Tokyo, Japan). Polypeptide concentrations were determined
using molar extinction coefﬁcients at 280 nm calculated with the
GPMAW program (Lighthouse data, http://www.gpmaw.com).
2.3. Protein chemistry
Our detailed protocols were published elsewhere [20]. Puriﬁed PT2
was reduced with dithiothreitol and alkylated with 4-vinylpyridine.
N-terminal sequencing was carried out by automated stepwise Edman
degradation using a Procise Model 492 protein sequencer (Applied
Biosystems) according to the manufacturer's protocol.
0.5 nmol of S-pyridylethylated PT2 was dissolved in 40 μl of 80% TFA,
and 1 μl of 5 M CNBrwas added. Themixturewas incubated overnight in
the dark. Reaction productswere separated by RP-HPLC on a Luna C18 col-
umn (1×150 mm, 100 Å, 3 μm; Phenomenex). The C-terminal fragment
was further redissolved in 40 μl of 100 mM Tris–HCl, pH 8.5. Hydrolysis
by endoproteinase Asp-N (Sigma-Aldrich; enzyme–protein ratio of
1/25) was performed at 37 °C for 4 h. The peptide fragments were sepa-
rated by RP-HPLC on the same Luna C18 column and analyzed byMS/MS.
2.4. Recombinant polypeptide production
All steps were performed as described earlier for PT1 [19]. cDNA
encoding recombinant PT2 (rPT2) was constructed from synthetic oligo-
nucleotides (Table 1) using PCR. The fragment was cloned at KpnI and
BamH1 restriction sites into the expression vector pET-32b (Novagen),
which was used to transform Escherichia coli Origami B cells for protein
production. rPT2 was produced as a fusion protein with thioredoxin,
which was puriﬁed on a TALON Superﬂow Metal Afﬁnity Resin
(Clontech) according to the protocol supplied by the manufacturer.
The purity of the hybrid proteinwas checked by sodiumdodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). The hybrid protein
was cleaved by human enterokinase catalytic subunit [21]; 1 unit per
1 mg of fusion protein, 4 h at 37 °C), and rPT2 was separated by means
of RP-HPLC on a Jupiter C4 semi-preparative column (250×10 mm,
300 Å, 10 μm; Phenomenex). The purity of rPT2 was checked by
MALDI MS as well as by N-terminal sequencing and RP-HPLC on a
Vydac 218TP54 C18 column.Table 1
Oligonucleotides used to construct the rPT2-encoding cDNA.
Primer
name
Sequence Length
F CGGGTACCGACGACGACGACAAGGCGAAAGCGTGCACGCCG 41
1f GCGAAAGCGTGCACGCCGCTGCTGCATGATTGTTCTCATGATCGCCACT 49
2f CCTGTTGTCGCGGCGATATGTTCAAGTATGTGTGCGACTGCTTCTACCC 49
3f GGAAGGCGAAGATAAGACGGAAGTGTGCTCTTGCCAGCAGCCGAAATCG 49
4f CACAAGATCGCGGAGAAGATCATCGACAAAGCGAAGACGACCCTGGGC 48
1/2r TATCGCCGCGACAACAGGAGTGGCGATCATGAGAAC 36
2/3r GTCTTATCTTCGCCTTCCGGGTAGAAGCAGTCGCAC 36
3/4r CTTCTCCGCGATCTTGTGCGATTTCGGCTGCTGGCA 36
R CGGGATCCTTAGCCCAGGGTCGTCTTCGC 292.5. P2X cloning
Full-length cDNA encoding the mouse P2X2 receptor (1509-bp)
was isolated from testis by RT-PCR with the primers 5′-TCTTGTG
GACCGAGCTCCTTG-3′ and 5′-AGGTCTGTAGCTTAGTGAGGATG-3′ and
was cloned into SmaI site of pIRES2-EGFP plasmid (Clontech). Mouse
P2X3 cDNA (1398-bp) was isolated from testis by RT-PCR with the
primers 5′-CTGTGAGCACTTTCTCAGTATG-3′ and 5′-ATTCAGGTCTTAGC
GGGAAGC-3′, TA-cloned into pGEM-T Easy plasmid (Promega), and
subcloned into EcoRI site of pIRES2-EGFP plasmid. Platinum Pfx DNA
polymerase (Invitrogen) was used for ampliﬁcation. The human P2X3
cDNA (EX-U0084-B02 clone) provided by GeneCopoeia was subcloned
into a pIRES2-EGFP vector by the authors.
2.6. Cell culture and transient transfection
Cells of the CHO line were routinely cultured in the F-12 Nutrient
Mixture (F-12) (Gibco) containing 10% fetal bovine serum (HyClone),
glutamine (1%) and the antibiotic gentamicin (100 μg/ml) (Invitrogen).
Cells were grown in 12-well culture plates in a humidiﬁed atmosphere
(5% CO2/95% O2) at 37 °C. The day before transfection, cells were trans-
ferred to 12-well culture plates at the density of 0.75–1×105 cells in
1 ml of F-12 per well. The recombinant plasmid pIRES2-EGFP/P2X3 or
pIRES2-EGFP/P2X2was transiently transfected into CHO cells by replac-
ing the growthmedium in eachwell with the transfectionmixture usu-
ally containing 1 μg of DNA and 3 μl of Unifectin-56 (Unifect Group) in
1 ml of serum-free F-12. For co-transfection, pIRES2-EGFP/P2X3 and
pIRES2-EGFP/P2X2 were taken at the ratio of 2:1. After 3 h of incuba-
tion, the transfectionmixturewas replacedwith the normal cultureme-
dium. Cells were assayed within 24–72 h after transfection.
2.7. Electrophysiology
Thewhole-cell patch clamp approachwas basically used. Ion currents
were recorded and ﬁltered at 1 kHz using an Axopatch 200A ampliﬁer, a
DigiData 1322A interface, and the pClamp8 software (Axon Instruments).
Recording pipettes had a resistance of 3–5 MΩ when ﬁlled with intra-
cellular solution containing (in mM): 140 CsCl, 1 MgATP, 10 BAPTA,
and 10 HEPES-CsOH (pH 7.2). This dialyzing solution was chosen to in-
hibit interfering endogenousK+channels andCa2+-dependent channels.
Cells were held at decreased potentials, typically at−30 mV, improving
stability of cellular preparations. To minimize variability of cellular re-
sponses to nucleotides during 40–60 min recordings, the series resis-
tance and cell capacitance were checked and compensated, if necessary,
prior every ATP/CTP application. The basic bath solution included (in
mM): 140 NaCl, 5 KCl, 1 MgCl2, 1 CaCl2, and 10 HEPES-NaOH (pH 7.4).
External solutions were delivered by a gravity-driven perfusion system
that allowed for a local exchange of the solution around the CHO cell for
200 ms and provided whole chamber perfusion at the rate of~0.1 ml/s
[22]. Experiments were carried out at room temperature of 22–25 °C.
3. Results
3.1. Purotoxin-2 (PT2) isolation and sequencing
The venom of the wolf spider Geolycosa sp. was investigated by us
earlier and found to contain components that target mammalian
neuroreceptors. In particular, ω-Lsp-IA modulating P-type calcium
channels [23] and purotoxin-1 (PT1) affecting P2X3 purinergic recep-
tors [19] were isolated and characterized in detail. Here we describe
yet another active polypeptide from the same venom. Similar to PT1,
it modulates P2X3 receptors and is therefore termed purotoxin-2 (PT2).
PT2was isolated from the crude venom using a conventional proce-
dure (Suppl. Fig. 1). The peptide-containing fraction obtained from size-
exclusion chromatography was further subjected to RP-HPLC, and PT2
2870 N.V. Kabanova et al. / Biochimica et Biophysica Acta 1818 (2012) 2868–2875was acquired with >95% purity, as assessed by analytical HPLC. Its mo-
lecular mass was determined by MALDI MS and equaled to 7255.5 Da.
The complete amino acid sequence of PT2was established by a com-
bination of Edman degradation and selective proteolysis (Fig. 1A). The
sequence was additionally veriﬁed by endoproteinase Asp-N cleavage
andMS/MS analysis of the fragments. PT2 consists of 64 amino acid res-
idues and features C-terminal amidation. This modiﬁcation was assigned
based on 1 Da difference between calculated and measured molecular
masses of the full toxin (7256.3 Da and 7255.5 Da, respectively) and its
C-terminal fragments. Eight cysteine residuesmost likely form4disulﬁde
bonds, given that non-reduced PT2 is not prone to modiﬁcation by
4-vinylpyridine, indicating the absence of free thiol groups. The polypep-
tide contains the principal structural motif (PSM) and extra structural
motif (ESM) and therefore belongs to the class 2 of spider toxins [24].
Both motifs probably contribute to the inhibitor cystine knot (ICK) fold,
which is typical for spider toxins [25,26].
3.2. Activity of P2X3 receptors in a heterologous system
To carry out a comparative study of PT1 and PT2 effects on mouse
(mP2X3) and human (hP2X3) P2X3 isoforms under identical condi-
tions, we used a heterologous system, that is, cultured CHO cells tran-
siently transfected with pIRES2-EGFP/P2X3 plasmid. Cells expressing
P2X3 at a sufﬁciently high level were identiﬁed by marked GFP ﬂuo-
rescence. For conclusive analysis, we accepted only recordings with
no profound rundown (b20%) of P2X3 currents within 40–60 min,
provided that PT1/PT2modulated those reversibly. Important for proto-
cols used here is the agonist-dependence of recovery of P2X3 receptors
from desensitization [27]. For example, recovery of ATP-gated currents
is nearly 10-fold slower than that of CTP-responses. With 30 μMATP as
agonist, the characteristic time of recovery has been estimated to be
~220 s and ~150 s for rat P2X3 andhP2X3, respectively [27,28]. To obtain
a sufﬁcient number of more or less reproducible nucleotide responses,
mP2X3-positive cells were stimulated mainly by CTP. In experiments
with hP2X3, ATP-gated currents exhibited a sufﬁciently short refractory
period, so that this natural P2X agonist was largely used to examine ef-
fects of the spider toxins on the hP2X3 isoform.
Given that initially, effects of a spider toxin, PT1, on P2X3 currents in
rat sensory neurons were explored at virtually saturating agonist con-
centrations [19], we examined amodulatory action of PT1 and PT2 on re-
combinant P2X3 receptors under similar conditions. We ﬁrst generated
dose–response curves for mP2X3/hP2X3 receptors to determine agonist
concentrations saturating CTP/ATP-gated currents in our heterologous
system. CHO cells transfected with mP2X3 or hP2X3 were stimulated
by CTP or ATP applied at different concentrations to generate dose–
response curves (Suppl. Fig. 2). Based on these dependencies, mP2X3
and hP2X3 currents were stimulated in further experiments by a brief
application of 100 μM CTP and 10 μM ATP, respectively.
An important feature of P2X3 receptors is the high-afﬁnity desen-
sitization. This phenomenon manifests itself through a marked de-
crease in a P2X3 current elicited by a short agonist pulse, if ambient
agonist is present in the bath at subthreshold nanomolar concentrations
[27,28]. Because this type of P2X3 desensitization turned out to be criti-
cally important for interpretation of PT1 and PT2 effects (see below), weFig. 1. PT1 and PT2 amino acid sequence. (A) Arrows below the PT2 sequence represent
C-terminal amidation is represented as –NH2. The lines above indicate putative disulﬁde bostudied this phenomenon in separate experiments. In a typical trial, a cell
transfectedwithmP2X3 (hP2X3)was stimulated by 100 μMCTP (10 μM
ATP) at least twice in control to obtain the averagedmagnitude of a P2X3
current (Fig. 2A, B, upper panels). Although affected a resting current
negligibly, the addition of subthreshold CTP (ATP) to the bath led to a
marked decrease in cellular responsivity to 100 μM CTP (10 μM ATP)
due to high-afﬁnity desensitization. The cell was stimulated 2–3 times
to determine the averaged value of the desensitized P2X3 current.
Next, the ambient nucleotide was carefully rinsed, and 100 μM CTP
(10 μM ATP) was applied again to reveal whether P2X3 current run-
down took place (Fig. 2A, B, upper panels). Note that ambient nucleo-
tide not only decreased responses to 100 μM CTP (10 μM ATP) but
also slowed down their desensitization (Fig. 2A, B, bottom panels). As
reported previously, the high-afﬁnity desensitization of P2X3 is accom-
panied by slowing down the recovery of P2X3 currents from classical
desensitization [28]. To prevent a possible inﬂuence of variable recovery
of P2X3 from desensitization on current magnitude, we stimulated
P2X3-positive cells by nucleotides as rarely as once per ~5 min and
carefully rinsed them afterward. Such an assay required prolonged re-
cordings so that rundown of P2X currents could occur. Therefore, a
given cell was assayed only at one particular concentration of ambient
CTP (ATP), and for further analysis, we took solely those cells that
exhibited almost complete recovery of a P2X3 current after removal of
an ambient agonist (Fig. 2A, B, upper panels).
Quantitatively, the high-afﬁnity desensitization was characterized
as the fractional inhibition F of a P2X3 current by an ambient agonist
at a given concentration A:
F ¼ I0−IA
I0
¼ A
n
An1=2 þ An
ð1Þ
where Io is the averaged P2X3 current in control, IA is the averaged P2X3
current desensitized by ambient CTP or ATP, n is the Hill coefﬁcient, A1/2
is the half-inhibition concentration. Fig. 2C summarizes overall experi-
mental data (symbols) that characterize the high-afﬁnity desensitiza-
tion of the mP2X3 current occurring in the presence of ambient CTP.
As a function of nanomolar CTP, the fractional inhibition F was ﬁtted
with Eq. (1) (solid line), giving n=2.2, A1/2=46.5 nM. The similar
analysis of hP2X3 currents (Fig. 2B) yielded the following values:
n=1.9, A1/2=2.67 nM ATP (Fig. 2D).
3.3. Effects of PT1 and PT2 on activity of P2X3 receptors
As found in earlier experiments with rat sensory neurons, P2X3
currents weremarkedly reduced in the presence of PT1 that also slowed
down P2X3 recovery from desensitization [19]. These PT1 effects were
dose-dependent with IC50=12 nM.We therefore expected PT1 tomod-
ulate P2X3 receptors from other mammalians, the mouse and human,
and considered the possibility that another spider toxin, PT2, also could
be effective.
Theoretically, these polypeptides could affect P2X3 currents by
means of changing the number of available channels, altering afﬁnity
to the particular agonist and/or inﬂuencing a degree and/or kinetics
of desensitization. For excluding a change in P2X current magnitudefragments determined by Edman degradation. Aspartic acid residues are underlined.
nds. (B) PT1 sequence.
Fig. 2. High-afﬁnity desensitization of P2X3 receptors. (A, B) Upper panels, the representative examples of sequentialmP2X3 (hP2X3) currents stimulated by a 2-s pulse of 100 μMCTP (10 μM
ATP) in control, in the presence of 70 nMCTP (3 nMATP), and after rinse of the ambient nucleotide. The applications of CTP (ATP) aremarked by the straight lines above the current traces. Cells
were held at−30 mV, perfused with a solution containing 140 mM NaCl, and dialyzed with a solution containing 140 mM CsCl. Bottom panels, the particular CTP (ATP) responses from A
(B) are superimposed in an enhanced time scale. The thick and thin lines and the circles correspond to the responses marked by *, ** and *** respectively. Each response was normalized to
its peak value. (C, D) P2X3 current elicited by 100 μM CTP (10 μMATP) versus ambient CTP (ATP) concentration. The data are presented as a mean±s.d. (n=3–5). The experimental depen-
dencies (symbols) were ﬁtted (solid lines) using Eq. (1) at n=2.2, A1/2=46.5 nM in C and n=1.9, A1/2=2.67 nM in D.
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ed P2X3-positive cells rarely enough and carefully rinsed them from
an agonist. When CTP-gated currents through mP2X3 were elicited
every 5 min, neither PT1 (n=7) (Fig. 3A) nor PT2 (n=5) (not
shown) exerted statistically signiﬁcant effects on cellular responses,
which magnitude and kinetics varied with time slightly and to the
same degree as control P2X3 currents (Fig. 3A, B, E). Meanwhile,
both polypeptides markedly decreased magnitude of mP2X3 currents
elicited by 100 μM CTP and slowed down their inactivation, provided
that nanomolar CTP was present in the bath (n=37) (Fig. 3C, D, E).
This suggested that PT1 and PT2 affected CTP-gated currents largely
by enhancing the high-afﬁnity desensitization of mP2X3 receptors.
Indeed, as shown in Fig. 3D, the control CTP response (marked by *)
inactivated more rapidly compared to the response (**) obtained with
50 nMCTP in the bath,while the additional deceleration of response in-
activation (***) was exerted by 50 nM PT2. Importantly, this action of
PT2 on kinetics of CTP-gated currents was reversible (Fig. 3C and D,
left panel). To quantify effects of ambient CTP and PT2 on mP2X3 inac-
tivation, the falling phase of a P2X3 current I(t)was ﬁtted at t≥ tp using
the equation:
I tð Þ=Ip ¼ δe−t=τ1 þ 1−δð Þe−t=τ2 ð2Þ
where Ip is the peak current at themoment tp. The kinetic analysis of nor-
malized cellular responses to 100 μM CTP in control and in the presenceof 50 nM CTP or 50 nM CTP+50 nM PT2 (Fig. 3D, right panel) yielded
the following averaged parameters (n=4), respectively: δ=0.85±
0.04. τ1=0.17±0.01 s, τ2=2.40±0.07 s; δ=0.68±0.03, τ1=0.19±
0.02 s, τ2=3.32±0.11; δ=0.65±0.03, τ1=0.26±0.03 s, τ2=4.88±
0.14 s. Thus, the effect of ambient CTP on the kinetics of P2X3 current
inactivation largely reduced to augmenting a contribution of the second
exponential component, compared to control, and increasing its charac-
teristic time τ2. PT2 markedly enhanced the effects of ambient CTP on
mP2X3 current inactivation. Although we did not perform the similar
kinetic analysis of effects of PT1 on mP2X3 current desensitized by
50 nM CTP, decelerated inactivation of those was well evident in all
cases (n=7), when both 50 nM CTP and 50 nM PT1 were present in
the bath (not shown).
In addition, we generated an inhibitory curve for fractional inhibi-
tion of the mP2X3 current by ambient CTP in the presence of 50 nM
PT1. It turned out that PT1 shifted the inhibitory curve of high-afﬁnity
desensitization to lower nucleotide concentrations (Fig. 3F). The ﬁt of
the experimental data with Eq. (1) showed that IC50 for ambient CTP
was decreased from 46.5 nM in control to 12.7 nM in the presence of
50 nM PT1.
The hP2X3 receptor was examined in a similar manner. As was the
case with CTP-gated currents through mP2X3 receptors (Fig. 3A, E),
50 nM PT1 or 50 nM PT2 alone negligibly affected the magnitude of
ATP-gated currents and kinetics of their inactivation, provided that
hP2X3-positive cellswere carefully rinsed fromATP (Fig. 4A, E). However,
Fig. 3. Effects of PT1 and PT2 on the mP2X3 receptor. (A) Representative recording demonstrating an insigniﬁcant effect of PT1 onmP2X3 activity in the absence of ambient CTP. The
P2X3 currents were elicited by a 2-s application of 100 μM CTP followed by continuous rinse with bath solution for ~5 min. The applications of CTP and 100 nM PT1 are marked by
the dots and straight lines above the current traces. (B) Superimposition in an enhanced time scale of the particular CTP responses from A, each being normalized to its peak value.
The solid line and circles correspond to the responses marked by * and **, respectively. (C) 50 nM PT2 enhanced the high-afﬁnity desensitization of CTP-gated currents elicited by
ambient CTP at 50 nM. (D) Left panel, the superimposition of the normalized CTP responses marked in C by * (thick line), ** (●), *** (thin line), and **** (o). Right panel, the falling
phases of the CTP responses in control (o), in the presence of 50 nM CTP (●) or 50 nM CTP+50 nM PT1 (Δ). These experimental curves were ﬁtted with the Eq. (2) (solid lines) at
the following parameters, correspondingly: δ=0.87, 0.69, 0.61; τ1=0.18, 0.19, 0.27 s; τ2=2.42, 3.27, 4.95 s. (E) Time evolution of mP2X3 currents exhibiting weak or negligible
rundown in control (o) (n=6), in the presence of 50 nM PT1 (●) (n=7), and in the presence 40 nM CTP and 50 nM PT1 (▲) (n=5) applied as indicated. The data are presented as
a mean±s.d. No statistically signiﬁcant difference between time courses of CTP responses in control (o) and in the presence of 50 nM PT1 (●) was found (pb0.05, Student-t-test).
In the particular recording, all CTP responses were normalized to the half sum of the ﬁrst two responses to 100 μM CTP. (F) mP2X3 current elicited by 100 μM CTP versus ambient
CTP concentration in control (▲) and in thepresenceof 50 nMPT1 (Δ). The solid lines correspond to Eq. (1) atn=2.2,A1/2=46.5 nM(thick line) and n=1.6,A1/2=12.7 nM(thin line). In
A–F, cells were held at−30 mV, perfused with a solution containing 140 mM NaCl, and dialyzed with a solution containing 140 mM CsCl.
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the magnitude of hP2X3 currents and slowed down their falling phases
(Fig. 4C, D, E). The kinetic analysis of cellular responses to 10 μM ATP
showed that under different conditions, the response inactivation was
well described by Eq. (2) (Fig. 4D, right panel), giving the following pa-
rameters on average (n=3): δ=0.85±0.04. τ1=0.16±0.02 s, τ2=
2.53±0.06 s in control, δ=0.72±0.04. τ1=0.18±0.02 s, τ2=3.48±
0.09 in the presence 2 nM ATP, and δ=0.64±0.03, τ1=0.25±0.03 s,
τ2=4.75±0.12 s with 2 nM ATP+50 nM PT1 in the bath. Qualitatively,
PT2 exerted similar deceleration of hP2X3 current inactivation (n=5)
(not shown). The comparison of the inhibitory curves for ambient ATP
generated in control and in the presence of PT2 revealed a decrease of
IC50 from 2.67 nM to 0.77 nM, respectively (Fig. 4F). Thus, the spider
toxins could inhibit the hP2X3 receptor by enhancing its high-afﬁnity de-
sensitization, as was the case with mP2X3 receptors (Fig. 3).3.4. Effects of PT1 and PT2 on activity of mP2X2/3 oligomeric receptors
Reportedly, certain P2X subunits form heteromeric ATP-gated
channels. The list particularly includes the P2X2/P2X3 heteromer,
which is involved in a variety of cellular functions, such as inﬂammatory
and neuropathic pain, urinary bladder reﬂex, enteric neurotransmission
and peristalsis, chemoreception, and taste transduction (reviewed in
[29,30]). Given the inhibitory effects of PT1 and PT2 on desensitizedP2X3 receptors (Fig. 3 and 4), we examined effects of these toxins on
the mP2X2/mP2X3 heteromer.
The separate transfection of CHO cells with mP2X2 or with mP2X3
rendered them speciﬁcally responsive to external ATP. In contrast to
mP2X3-positive cells (Fig. 3), activation of ATP-gated currents in
mP2X2-positive cells was relatively slow, and they inactivated much
less profoundly (Suppl. Fig. 3A). These ﬁndings are completely consis-
tent with the observations of others [3,30]. When co-transfected with
mP2X2 and mP2X3, CHO cells showed ATP-gated currents that were
kinetically distinct from those mediated by homomeric P2X receptors
(Suppl. Fig. 3A). Because ATP responses of the double-transfected
cells could not be ﬁtted using any linear combination of mP2X2 and
mP2X3 currents (Suppl. Fig. 3B), we inferred that just heteromeric
mP2X2/mP2X3 receptors were largely responsible for such ATP-gated
currents.
In agreement with previous results [19], 100 nM PT1 negligibly af-
fected ATP-gated currents through mP2X2 and mP2X2/3 receptors,
and 100 nM PT2 also exhibited negligible effects (not shown). In light
of results obtained with P2X3 currents (Fig. 3 and 4), we attempted to
elucidate whether ambient ATP could promote any effects of PT1 or
PT2 on mP2X2/3 receptors. It turned out that at subthreshold concen-
trations, ambient ATP affected negligibly ATP-gated currents per se.
Moreover, neither PT1 (not shown) nor PT2 (Fig. 5A) exerted speciﬁc
modulation of mP2X2/3 currents, judging by their magnitude and ki-
netics (Fig. 5B, C), in the presence of nanomolar ATP. Thus, our overall
Fig. 4. Effects of PT1 and PT2 on the hP2X3 receptor. (A) PT2 affected negligibly hP2X3 currents elicited by a 2-s application of 10 μMATP followed by continuous rinse with the bath
solution for ~5 min. 10 μM ATP and 100 nM PT2 were applied as indicated. (B) Superimposition of the particular ATP responses from A. The solid line and circles correspond to the
responses marked by * and **, respectively. Each response was normalized to its peak value. (C) 70 nM PT1 enhanced the high-afﬁnity desensitization of ATP-gated currents in the
presence of ambient ATP at 2 nM. (D) Left panel, the superimposition of the particular ATP responses from C normalized to the peak value. Right panel, the falling phases of the ATP
responses in control (o) and in the presence of 2 nM ATP (●) or 2 nM ATP+70 nM PT1 (Δ). The experimental curves were ﬁtted with the Eq. (2) (solid lines) at the following
parameters, correspondingly: δ=0.86, 0.72, 0.63; τ1=0.16, 0.18, 0.25 s; τ2=2.53, 3.48, 4.76 s. (E) Evolution of hP2X3 currents with time in control (●) (n=5) and in the presence
of 2 nM ATP and 50 nM PT2 (▲) (n=6) applied as indicated. The data are presented as a mean±s.d. In the particular recording, all ATP responses were normalized to the half sum
of the ﬁrst two responses to 10 μM ATP. (F) hP2X3 current elicited by 10 μM ATP versus ambient ATP concentration in control (▲) and in the presence of 50 nM PT2 (Δ). The solid
lines correspond to Eq. (1) at n=1.7, A1/2=2.67 nM (thick line) and n=1.4, A1/2=0.77 nM (thin line). Recording conditions were as in Fig. 3.
2873N.V. Kabanova et al. / Biochimica et Biophysica Acta 1818 (2012) 2868–2875data point out that the P2X3 receptor is a speciﬁc target for both PT1
and PT2 toxins.
4. Discussion
Ample evidence indicates that ATP is a nociceptive messenger and
that purinergic signaling is associated with nociception and pain (for
review see [31,32]. It was particularly shown that exogenous ATPFig. 5. PT2 does not modulate the heteromeric mP2X2/mP2X3 receptor. (A) Represen-
tative (n=16) ATP responses of a CHO cell transfected with the mP2X2 and mP2X3
subunits. The ATP-gated currents were elicited by a 6-s application of 10 μM ATP
marked by the straight lines above the recordings. (B) Particular ATP responses of
the mP2X2/mP2X3-positive cell indicated by the asterisks in A are presented in an en-
hanced time scale. (C) Superimposition of the ATP responses shown in B, each being
normalized to its magnitude. Recording conditions were as in Fig. 3.introduced into the skin generates burning pain in humans; both ATP
and α,β-methylene ATP, a P2X agonist, stimulated nociceptors in the
rat skin [33,34]. Administration of ADP-β-S, a P2Y1, P2Y12 and P2Y13
agonist, inhibited spinal nociceptive transmission and nocifensive be-
havior [35], and infusion of the P2Y1 agonist MRS2365, P2Y12 antago-
nist MRS2395, and P2Y2/P2Y4 agonist UTP signiﬁcantly alleviated
mechanical allodynia in the neuropathic pain model [36].
Nociceptive neurons predominantly express P2X2 and P2X3 subunits
[37,38]. Several experimental models corroborate the involvement of
P2X2 and P2X3 receptors in the development of nerve injury-induced
mechanical hypersensitivity. It was shown that nocifensive behavioral
responses developed after injury could be reversed by P2X receptor an-
tagonists, and inhibition of P2X2 and P2X3 led to a reduction in Aδ and
C-ﬁber activity elicited by nerve injury [37,39]. Somewhat similar results
were obtained in studies of animals deﬁcient in P2X2 and P2X3 receptors
[17,40]. Although P2X3 receptor antagonists do not affect acute pain sen-
sitivity, they deﬁnitely have analgesic action in inﬂammatory and neuro-
pathic pain models [39,41]. Thus, selective antagonists for P2X3 and/or
P2X2/3 receptors may constitute a basis for novel analgesic drugs [31].
4.1. PT2 is a novel peptide modulator of mammalian P2X3 receptors
P2X3 receptors are targeted by a great number of low-
molecular-weight substanceswith a varying degree of afﬁnity and spec-
iﬁcity [42]. Prior to this work, only two peptides have been reported to
speciﬁcally modulate activity of mammalian P2X3 receptors, namely,
purotoxin-1 (PT1) [19] and spinorphin [43]. The latter is known to in-
hibit enkephalin-degrading enzymes as well [44]. Purotoxin-2 (PT2)
2874 N.V. Kabanova et al. / Biochimica et Biophysica Acta 1818 (2012) 2868–2875described here is in fact a novel polypeptide from structural and func-
tional points of view. Despite common origin, that is, the Geolycosa sp.
venom, there is no signiﬁcant similarity between PT2 and PT1, except
for the PSM and ESM motifs and the ICK signature. Meanwhile, PT2
shows close similarity with certain LSTX toxins from Lycosa singoriensis
identiﬁed by transcriptome analysis of the venom glands [45]. Lower
but still considerable similarity takes place between PT2 and CSTX
toxins from Cupiennius salei [46], including the CSTX-13 toxic enhancer
[47]. It is interestingwhether some LSTX and/or CSTX toxins are capable
ofmodulating P2X3 receptors. If so, PT2 can be considered as the founder
of a new purotoxin family.
4.2. PT1 and PT2 promote the high-afﬁnity desensitization of P2X3 receptors
Based on physiological activity of PT1 revealed with animal models
and sensory neurons [19], we questioned whether PT1 and PT2 might
modulate recombinant P2X3 receptors. We expressed heterologously
murine and human P2X3 receptors in CHO cells. Note that unlike
hP2X3, ATP-gated currents through mP2X3 were characterized by an
inappropriately long refractory period, thus preventing a recording of
a suitable number of reproducible cellular responses. For this reason,
mP2X3 and hP2X3 were stimulated by CTP and ATP, respectively.
Two different modes have been reported for the PT1 action on P2X3
currents in rat DRG neurons [19]: when applied to nondesensitized re-
ceptors, PT1 potentiated P2X3 currents, while current inhibition took
place, if the desensitized receptor was treated with PT1. Here we
studied recombinant mP2X3 and hP2X3 receptors and found that nei-
ther PT1 nor PT2 (up to 100 nM) exerted statistically signiﬁcant poten-
tiation or inhibition of CTP or ATP-gated currents, provided that
ambient CTP or ATP was carefully rinsed (Fig. 3A, B and 4A, B). Perhaps,
somewhat different recording protocols and/or difference between
species-related P2X3 receptors and/or cell-speciﬁc microenvironment
underlay the mentioned inconsistency between the data present here
and the results obtained with rat DRG neurons [19].
In our experiments, P2X-positive cells became evidently sensitive to
the spider toxins, only if CTP/ATPwaspresent in the bath at subtheshold
nanomolar concentrations. With ambient nucleotides in the external
solution, the addition of 50–70 nM PT1 or PT2 to the bath invariably
resulted in a marked reduction of CTP/ATP-gated currents and decel-
eration of their inactivation (Fig. 3C, D and 4C, D). This indicated that
ambient nucleotide was a necessary cofactor rendering P2X3 receptors
sensitive to the spider toxins. Both PT1 and PT2 appeared to enhance
the high-afﬁnity desensitization of P2X3 receptors. It was particularly
found that at the concentration of 50 nM, the polypeptides, PT1 for
mP2X3 and PT2 for hP2X3, shifted inhibitory curves for the high-afﬁnity
desensitization of P2X3 receptors, eliciting a nearly 3-fold decrease in
the IC50 dose for an ambient nucleotide (Fig. 3F and 4F).
The elucidated mode of the inhibitory action of PT1 and PT2 on P2X3
activity is rather exceptional: they exert no effects on slow-desensitizing
P2X2 and P2X2/3 subtypes of purinoreceptors (Fig. 5) but selectively
affect the fast-desensitizing P2X3 subtype, most likely by recognizing
solely a desensitized conformation of the receptor. To our knowledge,
only P1,P5-di[inosine-5′] pentaphosphate, a noncompetitive antagonist
of fast-desensitizing P2X1 and P2X3 purinoceptors, is capable of acting
in a somewhat similar mode by binding the desensitized conformation
[48]. However, the relatedness of its effects to the high-afﬁnity desensi-
tization remains non-investigated.
In conclusion, our data indicate that the larger fraction of P2X3 re-
ceptors gets the high-afﬁnity desensitization, themore profound effects
of the PT1 and PT2 toxins on P2X3 currents could be expected. Although
ATP abundance in intercellularmilieu is not knownwith conﬁdence, the
estimates available for certain tissues range a concentration of ambient
ATP fromhundreds pM to dozens nM [49,50]. This points out that in vivo,
the high-afﬁnity desensitization may control P2X3 receptor functions in
response to a phasic ATP release, especially in inﬂammatory tissues. If
so, administration of PT1 and PT2 should enhance the high-afﬁnitydesensitization of P2X3. This may account for the analgesic effect of the
PT1 peptide documented in the animal model of inﬂammation [19].
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